Clinical trial
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
NCT00068432 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00068432 |
|---|---|
| Title | Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer |
| Official title | A Phase II Trial of Gemcitabine and Celecoxib as First-Line Treatment for Patients With Advanced Metastatic Pancreatic Cancer |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | Celecoxib, Gemcitabine Hydrochloride |
| Enrollment | 28 |
| Start date | Dec 1, 2003 |
| Primary completion | Jul 1, 2005 |
| Completion | Jul 1, 2005 |
| First posted | Sep 11, 2003 |
| Last update posted | Oct 31, 2018 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: